Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · November 18, 2016

2016 Top Stories in Oncology: Aromatase Inhibitors in Breast Cancer

Jeffrey Kirshner MD, FACP, FASCO

 

 Save  Recommend
 Share

Additional Info

  1. Goss PE, Ingle JN, Pritchard KI, et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract LBA1.
  2. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209-219.

Further Reading

Most Read This Week

Recently Updated